Objective-To evaluate olfactory function in Parkinson's disease. Methods.-A standardised odour identification test was used, together with an evoked potential assessment with hydrogen sulphide. In addition, histological analysis was performed on the olfactory bulbs of cadavers who died from Parkinson's disease. Results-Over 70% of patients studied (71 of 96) were outside the 95% limit of normal on the identification test in an age matched sample and there was an unusual pattern of selective loss to certain odours, not hitherto described. The evoked potentials were significantly delayed but of comparable amplitude to a control matched population. Of the 73 patients studied only 37 had a technically satisfactory record containing a clear response to both gases and of these, 12 were delayed.
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Abstract Objective-To evaluate olfactory function in Parkinson's disease. Methods.-A standardised odour identification test was used, together with an evoked potential assessment with hydrogen sulphide. In addition, histological analysis was performed on the olfactory bulbs of cadavers who died from Parkinson's disease. Results-Over 70% of patients studied (71 of 96) were outside the 95% limit of normal on the identification test in an age matched sample and there was an unusual pattern of selective loss to certain odours, not hitherto described. The evoked potentials were significantly delayed but of comparable amplitude to a control matched population. Of the 73 patients studied only 37 had a technically satisfactory record containing a clear response to both gases and of these, 12 were delayed. For H,S there was more delay on stimulating the right nostril than the left. Some patients with normal smell identification test scores had delayed evoked potentials. In the pathological examination of olfactory bulbs from eight brains, changes characteristic of Parkinson's disease (Lewy bodies) were seen in every olfactory bulb, particularly in the anterior olfactory nucleus, and were sufficiently distinct to allow a presumptive diagnosis of Parkinson's disease. Conclusions Kobal and Plattig2 and adopted by us. ' The basal ganglia have been the subject of intense pathological study in Parkinson's disease, but the rhinencephalon has not been investigated systematically. Chui et a14 examined four patients with Parkinson's disease with dementia and in one brain found an Alzheimer type change in the amygdala, adjacent anterior temporal cortex, and CA2 sector of the hippocampus. The hippocampus was normal in the remaining three cases. It is uncertain whether all the central olfactory areas were examined. Furthermore, the cases were complicated by the presence of dementia.
We have undertaken a multidisciplinary study of olfactory identification, olfactory evoked potential, and pathological examination of the olfactory bulb in Parkinson's disease.
Methods
After local ethics committee approval and informed consent of patients and controls we undertook the procedures described below.
were examined neurologically at least once by one of us (CHH) and were considered to have idiopathic Parkinson's disease although we are well aware of the roughly 25% fallibility of such classification.6 All patients had intact nasal passages on routine bedside examination and scored 27/30 or more on the mini mental test. If questionnaire analysis suggested nasal disease or any other condition that might impair olfaction (for example, diabetes, severe head trauma, alcoholism) they were excluded. Despite these precautions we are aware that nasal disease may still be present even in apparently healthy people.7 Nearly all the patients with Parkinson's disease were receiving levodopa and selegiline but these probably do not affect the ability to smell.89 We made no specific tests for depression. Six patients were taking long term tricyclic antidepressants in small doses and two were on long term lithium carbonate for affective disorder. Impairment of sense of smell has not been found in patients with depression (Amsterdam et al10 and our own findings). The effect of depression on olfactory evoked potentials is not known but we suspect that it is unimportant as long as the patient is cooperative.
OLFACTORY EVOKED POTENTIALS
The term olfactory evoked potential is used in this article to refer to both H2S and CO2
responses. CO2 has no odour and is a stimulant of trigeminal nerve endings in the nose.
The olfactory stimulator we used is similar in construction and design to that described by Kobal" except that our solenoid valves have a slower response time (see below). The stimulator overcomes the problem of inadvertent trigeminal stimulation. Anosmic patients tested with this device show no response to primarily olfactory stimulants such as H,S (Kobel and Hummel"2 and our own findings). Olfactory stimuli are embedded in an odourless bacteriologically pure carrier gas. This is achieved by passing compressed air through a series of five filters. The gas flows at 140 ml/s and is heated and humidified to match the nasal environment. The principle of stimulus generation is to have two identical gas flows-only one of which contains the odorous substance. Either of the flows can be directed to the nose (fig 1) . The air stream is delivered to the nose by means of a teflon tube with a nozzle (internal diameter 4 mm) inserted about 1 cm into one nostril. Between stimuli, only clean air enters the nasal cavity and the air stream containing the odour is vented outside the recording room. Stimulation is carried out by switching the two flows for a preset time using two valves (Festo Ltd) with a fast response time. This eliminates detectable pressure change at the nose and therefore avoids trigeminal activity due to pressure changes. The duration of stimulus containing the test gas is set to 200 ms in all cases. The characteristics of the pulse have been ascertained by a low flow meter (Si-Plan UK Ltd). The rise time measured at the end of the nasal tubing is approximately 34 ms. This is a composite figure derived from the switching periods of the valves (approximately 10 ms); travel along the insulated tubing from the nose to the intranasal cannula (approximately 20 ms); and response time of the flow meter itself of 4 Specificity waveform was detectable in an artefact free recording. Forty seven controls were used for both gases as described in the methods section.
Carbon dioxide (50% concentration volumelair in all cases) Sixty six patients with Parkinson's disease were tested initially but six were rejected: five had unclear recordings and one was absent. This left 60 patients and there were only 37 who responded to both CO2 and H2S. Figure   6A shows the olfactory evoked response at CZ due to stimulation by CO2 for a selection of patients with Parkinson's disease.
Hydrogen sulphide (20 For CO2 and H2S in controls there was significant correlation of UPSIT score with Ni-P2 amplitude (P < 0006, r = 037 for CO2; P < 0-001, r = 0-44 for H2S) and for latency (P < 0-05, r = -0-29 for CO2 to P2 only; P < 0-05; r = -0-25 for H2S to NI only). For CO2 in patients there was no correlation of UPSIT score with latency or amplitude measurements. For H2S in patients there was correlation of Ni and P2 latency (P < 0-001 r = -0 54; P < 0-001, r = -0-62 respec- The UPSIT data for Parkinson's disease are similar to those described by Doty and colleagues' except that our series is slightly larger and contains more young patients-down to 27 years. These authors suggested that olfactory dysfunction was unrelated to odour type, did not depend on disease duration, and did not correlate with motor function, tremor, or cognition, as was also found by others.9 Doty et a18 also showed that the deficit was of the same magnitude in both nostrils, and was not influenced by antiParkinsonian medication. As reported by Doty et al' we also found no correlation of UPSIT with duration of disease. Whereas there was clearly a background depression of olfactory identification, superimposed on this was a degree of selective odour deficit-something that was not documented by Doty's group. Odours that were most readily misidentified were lemon, pizza, wintergreen, rose, and clove. Pizza was the best single discriminant odour with pizza and wintergreen in combination better still. Thus a subject could be suspected of having Parkinson's disease if both pizza and wintergreen were inaccurately identified and would probably not have the disease if both of these odours were positively smelt correctly (not by random guessing). Because subjects made a forced choice of one from four possibilities, 25% will be correct by chance alone. Hence a sensitivity value of 76% for pizza in the presence of 90% specificity indicates anosmia to pizza for patients with Parkinson's disease. It is difficult to explain why this should be. Controls and patients were matched for age and sex as these variables influence the UPSIT score in Parkinson's disease.'4 We did not have sufficient numbers to match for other factors which might influence the result, such as intelligence or social class; nor were we able to allow for variation in odour intensity due to errors in manufacture. Although lemon, wintergreen, and clove have some trigeminal stimulation, pizza (oregano smell) and certainly rose are mainly olfactory. Whatever the mechanism, these findings raise the possibility that there may be a congenital or acquired selective hyposmia in Parkinson's disease comparable with androstenone smell blindness which affects 20%-47% of healthy people.'5 Of particular relevance is a study in which rats were exposed to 44 inhaled vapours for several weeks. '6 is a reduction of N1-P2 gradient causing a broader wave shape. In our earlier study of multiple sclerosis there was significant change in latency.' Because Parkinson's disease is not a demyelinating condition we did not expect to find a latency change and can offer no explanation for this at present. Our patient and control groups are not well matched for age. As there are more elderly patients than controls this might inflate any difference between the two groups, especially in the older age range. However, age was allowed for in the regression analysis. The large number of absent responses (27 of 73) was partly due to technical difficulty in obtaining the olfactory evoked potential, which is considerably greater than comparable procedures such as visual, auditory, and somatosensory responses. Apart from the need for repeated checking of the signal it is possible to average 20 signals at most because of the necessarily prolonged interstimulus interval (60 seconds) required. It is not surprising that so many were absent as the patients with Parkinson's disease had a poor sense of smell generally and the few delayed H,S responses in those we could test may be a reflection of a healthier population in the olfactory sense. Sometimes technical difficulties brought the recording session to a premature halt or a problem was experienced with involuntary movement, making it difficult for the patient to keep the tubing in the nose.
Even in healthy controls six of 69 (7%) H,S recordings were unsuccessful. For CO,, responses were unobtainable in six of 66 (9%) patients and six of 56 (9%) controls. The number of healthy controls used was reduced to 47 as we accepted only those with responses to both gases. All controls who were rejected tolerated 40% CO, but they had to be excluded because of intolerance to 50% CO,.
The UPSIT is the superior test with more than 70% abnormality in Parkinson's disease. This contrasts with 12 of 37 (32%) delayed responses to H,S in patients. A record which is labelled absent may in fact contain a response which is below the limit of detection imposed by averaging 16 signals. We have used only one odour whereas the UPSIT implements 40. If three or four different gases were used the sensitivity of olfactory evoked potentials might well increase.
The correlation of UPSIT score with latency and amplitude measurements in controls for H2S is to be expected as identification might well be easier with a more vigorous cerebral signal. This association does not hold good for patients exposed to H2S in whom the correlation is strong with latency but not amplitude.
In one study ' An alternative hypothesis could be constructed around the finding that some patients with Parkinson's disease exhibit a defect in the P-450 cytochrome CYP2D6-debrisoquine hydroxylase gene.'6 Mammalian P-450 dependent oxygenases provide a central line of defence against exogenous toxins and it has been shown that the risk of Parkinson's disease is more than doubled for those with a P-450 genetic polymorphism associated with deficient debrisoquine metabolism. The high concentration of P-450 in hepatic microsomes is well known and it has been shown that microsomes in the olfactory epithelium of, for example, the rat27 and rabbit28 have high concentrations of P-450, sometimes in excess of those in the liver depending on the particular subtype. The 
